Technology | Vascular Closure Devices | April 17, 2018

FDA Approves Abbotts Perclose ProGlide Suture-Mediated Closure System for Femoral Vein Closures

System closes large-bore catheter access sites in large vessels with a single suture

FDA Approves Abbotts Perclose ProGlide Suture-Mediated Closure System for Femoral Vein Closures

April 17, 2018 — The U.S. Food and Drug Administration (FDA) announced market approval for the Abbott Perclose ProGlide Suture-Mediated Closure System, designed to deliver a single suture to close the access sites in large vessels in the leg following catheterization procedures.

The ProGlide is used after the insertion of large-bore catheters and is able to close access sites ranging from about 0.07 inches to 0.32 inches in diameter. The system is composed of a plunger, handle, guidewire and sheath. The surgeon places the ProGlide over a guidewire and inserts the end of the device into the blood vessel. The surgeon presses the plunger and lever on the handle of the device, which maneuver the suture to create a stitch across the access site.

In some cases (3 out of 10), in addition to the ProGlide stitch, pressure may need to be applied to the access site to fully stop blood flow. When catheters larger than about 0.1 inches in diameter are used during the catheterization procedure, two ProGlide devices are necessary to close the access site.

For more information: www.abbottvascular.com

 

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init